Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NC-ND 4.0Translational Breast Cancer Research

Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib

  • Stefan Lukac1
  1. 1Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany
Read full textDOICite

Related

  1. Response-adapted de-escalation in human papilloma virus-related oropharyngeal squamous cell carcinoma.
    John W R Kincaid, Jonathan D Schoenfeld, Mina Bakhtiar
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer.
    Dylan S Brokaw, Leonardo Kozian, Cecilia Chang +5
    Breast cancer research and treatmentPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy
    Ilke Aernout, Thomas Ehouarne, Kevin Mwangi +14
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textInfectious diseaseCrossrefEurope PMC
  4. Abemaciclib plus endocrine therapy in high-risk, node-positive early breast cancer in Italian practice: interim analysis of prospective observational IT-PATH study.
    L Visani, A Melaccio, C Vernieri +17
    ESMO real world data and digital oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Precision de-escalation in HER2-enriched breast cancer: promise and pitfalls of multiomic response predictors
    Jessé Lopes da Silva, Andréia Cristina de Melo
    Translational Breast Cancer ResearchPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{lukac2026start,
  title = {{Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib}},
  author = {Stefan Lukac},
  journal = {Translational Breast Cancer Research},
  year = {2026},
  month = sep,
  doi = {10.21037/tbcr-2026-0039},
  url = {https://doi.org/10.21037/tbcr-2026-0039},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib
AU  - Stefan Lukac
PY  - 2026
DA  - 2026/09/30
JO  - Translational Breast Cancer Research
DO  - 10.21037/tbcr-2026-0039
UR  - https://doi.org/10.21037/tbcr-2026-0039
SN  - 2218-6778
ER  -